Floatz logo

Pirfenidone

Liver Fibrosis

Grupo Mexicano para el Estudios de las Enfermedades HepaticasSmall moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Liver Fibrosis cohort.

Asset / SponsorPhaseRating
Entecavir
Tanta University
Phase 4BB
COLCHICINUM
Zagazig University
Phase 4BB
Peg-Intron
Beth Israel Deaconess Medical Center
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB

View all 50 →

Same molecule, other indications

Pirfenidone is also rated in:

idiopathic pulmonary fibrosisDormant
A
Indicative ·
80 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
66 / 100
View asset →
liver disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →